Project Details
Description
PROJECT SUMMARY/ABSTRACT
Breast cancer (BC) remains the most commonly diagnosed cancer in premenopausal women (pre-MW)
worldwide and its incidence is increasing in developed countries. BCs in pre-MW are more likely to be of an
aggressive intrinsic subtype, higher grade, and advanced stage compared to BCs in post-MW. Pre-MW with
ER+/HER2- BC are commonly treated with chemotherapy (CT), endocrine therapy (ET) and ovarian function
suppression (OFS). Long-term data from the SOFT and TEXT adjuvant trials demonstrated that aromatase
inhibitors (AI)+OFS improved disease free survival but have yet to improve overall survival (OS), compared to
tamoxifen (TAM) or TAM+OFS. Furthermore, in one study (ABCSG 12), AI+OFS led to worse OS compared to
TAM+OFS. The lack of a survival benefit in these studies may relate to the detrimental side-effects of premature
menopause (PM), known to be associated with higher rates of cardiac disease, hypertension, diabetes,
hyperlipidemia, osteoporosis and death. Therefore, alternative endocrine strategies for pre-MW with ER+/HER2-
BC are critically needed, especially for pre-MW who cannot tolerate OFS. Endoxifen (ENDX) is an active TAM
metabolite, and the PI’s have led the development of ENDX as a novel ET for BC. Through completion of phase
I and II trials, we have demonstrated that ENDX is safe, well-tolerated, has substantial oral bioavailability and is
superior to TAM in endocrine therapy (ET) resistant BC. Furthermore, the PI’s have identified a novel mechanistic
basis for the superior anti-cancer effects of ENDX; namely, the novel ENDX target, PKCβI. Here, we build upon
this foundation by performing a prospective neoadjuvant endocrine study comparing ENDX without OFS vs
AI+OFS in the neoadjuvant treatment of pre-MW with ER+/HER2- BC. We will also extensively study the roles
of PKCβI in mediating ENDX efficacy, given our preliminary data demonstrating that ENDX uniquely binds PKCβI
and targets it for proteasomal degradation, resulting in downregulation of ERα, cyclin D1, and E2F1 protein levels
concurrent with marked inhibition of BC cell proliferation. Importantly, these effects are not observed with PKCβI
kinase inhibitors, suggesting novel non-kinase related functions of PKCβI. Furthermore, they are not observed
with TAM or AI. Based on these data, the central hypothesis of this proposal is that ENDX is a superior ET in
part due to its ability to dually target both ER and PKCβI. We further hypothesize that the optimal treatment of
pre-MW with ER+/HER2- BC can be achieved using ENDX monotherapy without the need for OFS. To test our
hypotheses, we will 1) develop ENDX for pre-MW with ER+/HER2- BC; 2) elucidate the mechanisms by which
PKCβI contributes to ENDX responsiveness in endocrine sensitive disease; and 3) determine the predictive and
prognostic value of PKCβI in ER+/HER2- BC patients treated with TAM and ENDX. Given the increasing
incidence of BC in pre-MW, along with the known morbidity associated with OFS, the proposed studies are of
critical importance towards improving the endocrine management of ER+/HER2- BC in pre-MW.
Status | Finished |
---|---|
Effective start/end date | 9/21/22 → 8/31/23 |
Funding
- National Cancer Institute: $279,341.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.